Despite a challenging capital environment, early-stage biotech venture financing showed resilience in the first half of 2025. Seed and Series A rounds increased compared to the previous year, though the total number of companies raising funds declined. Four companies accounted for nearly a quarter of the $4.7 billion raised, highlighting continued investor focus on select firms with high growth potential. The capital flow reflects sustained industry enthusiasm for innovative biopharma ventures, particularly in Asia.